Lex­i­con ends com­mer­cial work to fo­cus on R&D

Lex­i­con Phar­ma­ceu­ti­cals is re­vert­ing to a clin­i­cal de­vel­op­ment com­pa­ny af­ter fac­ing re­peat­ed set­backs at the FDA for its type 1 di­a­betes and chron­ic kid­ney dis­ease …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER